Fig. 1.
VASH2 expression is associated with gemcitabine resistance in pancreatic cancer. Kaplan-Meier survival analysis results of 102 cases of pancreatic cancer. a survival analysis of patients with negative/weak VASH2 staining tumors treated with or without gemcitabine chemotherapy. b survival analysis of patients with middle/strong VASH2 staining tumors treated with or without gemcitabine chemotherapy. c survival analysis of patients treated with gemcitabine chemotherapy with negative/weak or middle/strong VASH2 staining tumors. d survival analysis of patients who received no chemotherapy with negative/weak or middle/strong VASH2 staining tumors